You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNevirapine
Accession NumberDB00238  (APRD00705, DB08311)
TypeSmall Molecule
GroupsApproved
Description

A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. [PubChem] Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.

Structure
Thumb
Synonyms
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
NEV
Nevirapine
NVP
Viramune
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-nevirapinetablet200 mgoralAurobindo Pharma Limited (Unit Iii)2010-12-29Not applicableCanada
Mylan-nevirapinetablet200 mgoralMylan Pharmaceuticals Ulc2012-06-20Not applicableCanada
Nevirapinesuspension50 mg/5mLoralRoxane Laboratories, Inc.2012-05-21Not applicableUs
Nevirapinetablet200 mg/1oralRoxane Laboratories, Inc.2012-05-21Not applicableUs
PMS-nevirapinetablet200 mgoralPharmascience Inc2013-06-03Not applicableCanada
Teva-nevirapinetablet200 mgoralTeva Canada Limited2011-02-01Not applicableCanada
Viramunetablet200 mgoralBoehringer Ingelheim (Canada) Ltd Ltee1998-09-17Not applicableCanada
Viramunetablet, extended release400 mg/1oralPhysicians Total Care, Inc.2013-01-23Not applicableUs
Viramunetablet200 mg/1oralA S Medication Solutions2001-08-01Not applicableUs
Viramunetablet200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Viramunetablet, extended release100 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2013-03-01Not applicableUs
Viramunetablet, extended release400 mg/1oralBoehringer Ingelheim Pharmaceuticals, Inc.2011-04-11Not applicableUs
Viramunesuspension50 mg/5mLoralBoehringer Ingelheim Pharmaceuticals Inc.2001-10-01Not applicableUs
Viramunetablet200 mg/1oralBoehringer Ingelheim Pharmaceuticals Inc.2001-08-01Not applicableUs
Viramune XRtablet (extended-release)400 mgoralBoehringer Ingelheim (Canada) Ltd Ltee2011-09-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nevirapinetablet200 mgoralApotex IncNot applicableNot applicableCanada
Apo-nevirapine XRtablet (extended-release)400 mgoralApotex Inc2015-11-24Not applicableCanada
Nevirapinetablet200 mg/1oralAurobindo Pharma Limited2012-05-22Not applicableUs
Nevirapinetablet200 mg/1oralAmneal Pharmaceuticals of New York, LLC2014-04-30Not applicableUs
Nevirapinetablet200 mg/1oralCipla Limited2012-05-22Not applicableUs
Nevirapinetablet200 mg/1oralMylan Pharmaceuticals Inc.2012-05-22Not applicableUs
Nevirapinetablet, coated200 mg/1oralCarlsbad Technology, Inc.2016-01-01Not applicableUs
Nevirapinetablet200 mg/1oralBreckenridge Pharmaceutical, Inc.2011-04-11Not applicableUs
Nevirapinetablet, extended release400 mg/1oralApotex Corp2014-04-15Not applicableUs
Nevirapinetablet200 mg/1oralApotex Corp2012-05-22Not applicableUs
Nevirapinetablet200 mg/1oralAlvogen Inc.2012-05-22Not applicableUs
Nevirapinetablet200 mg/1oralGolden State Medical Supply, Inc.2012-05-22Not applicableUs
Nevirapinetablet200 mg/1oralCamber Pharmaceuticals, Inc.2012-05-23Not applicableUs
Nevirapinetablet200 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Nevirapinetablet, extended release400 mg/1oralSandoz Inc2014-04-15Not applicableUs
Nevirapinetablet, extended release400 mg/1oralCipla USA Inc.2015-10-15Not applicableUs
Nevirapinetablet200 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Nevirapinetablet, extended release100 mg/1oralMylan Pharmaceuticals Inc.2015-11-09Not applicableUs
Nevirapinetablet200 mg/1oralAmneal Agila, Llc2014-04-30Not applicableUs
Nevirapinetablet, extended release400 mg/1oralMylan Pharmaceuticals Inc.2014-10-29Not applicableUs
Nevirapine Extended Releasetablet400 mg/1oralAlvogen Inc.2015-07-14Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Apo-zidovudine-lamivudine-nevirapineApotex Inc
SaltsNot Available
Categories
UNII99DK7FVK1H
CAS number129618-40-2
WeightAverage: 266.2979
Monoisotopic: 266.11676109
Chemical FormulaC15H14N4O
InChI KeyInChIKey=NQDJXKOVJZTUJA-UHFFFAOYSA-N
InChI
InChI=1S/C15H14N4O/c1-9-6-8-17-14-12(9)18-15(20)11-3-2-7-16-13(11)19(14)10-4-5-10/h2-3,6-8,10H,4-5H2,1H3,(H,18,20)
IUPAC Name
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
SMILES
CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassTertiary amines
Direct ParentAlkyldiarylamines
Alternative Parents
Substituents
  • Alkyldiarylamine
  • Pyrido-para-diazepine
  • Methylpyridine
  • Para-diazepine
  • Imidolactam
  • Pyridine
  • Heteroaromatic compound
  • Vinylogous amide
  • Secondary carboxylic acid amide
  • Lactam
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
PharmacodynamicsNevirapine is a non-nucleoside reverse transcriptase inhibitor (nNRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). HIV-2 RT and eukaryotic DNA polymerases (such as human DNA polymerases alpha, beta, or sigma) are not inhibited by nevirapine. Nevirapine is, in general, only prescribed after the immune system has declined and infections have become evident. It is always taken with at least one other HIV medication such as Retrovir or Videx. The virus can develop resistance to nevirapine if the drug is taken alone, although even if used properly, nevirapine is effective for only a limited time.
Mechanism of actionNevirapine binds directly to reverse transcriptase (RT) and blocks the RNA-dependent and DNA-dependent DNA polymerase activities by causing a disruption of the enzyme's catalytic site. The activity of nevirapine does not compete with template or nucleoside triphosphates.
Related Articles
AbsorptionNevirapine is readily absorbed (greater than 90%) after oral administration in healthy subjects and adults with HIV-1 infection. The absolute bioavailability in healthy adults following a single dose administration is 93 ± 9% (mean ± SD) for a 50 mg tablet and 91 ± 8% for an oral solution. Peak plasma nevirapine concentrations of 2 ± 0.4 mcg/mL (7.5 micromolar) were attained by 4 hours following a single 200 mg dose. Nevirapine tablets and suspension have been shown to be comparably bioavailable and interchangeable at doses up to 200 mg. When the oral tablet is given with a high-fat meal, the extent of absorption is compared to that of the fasted-state.
Volume of distribution
  • 1.21 ± 0.09 L/kg [apparent volume of distribution, healthy adults, IV]
    Nevirapine is capable of crossing the placenta and is found in breast milk.
Protein binding60% bound to plasma protein.
Metabolism

Hepatic. In vivo studies in humans and in vitro studies with human liver microsomes have shown that nevirapine is extensively biotransformed via cytochrome P450 3A4 metabolism to several hydroxylated metabolites.

SubstrateEnzymesProduct
Nevirapine
12-HydroxynevirapineDetails
Nevirapine
2-HydroxynevirapineDetails
Nevirapine
8-HydroxynevirapineDetails
Nevirapine
3-HydroxynevirapineDetails
12-Hydroxynevirapine
Not Available
12-hydroxynevirapine glucuronideDetails
12-Hydroxynevirapine
4-carboxynevirapineDetails
2-Hydroxynevirapine
Not Available
2-hydroxynevirapine glucuronideDetails
8-Hydroxynevirapine
Not Available
8-hydroxynevirapine glucuronideDetails
3-Hydroxynevirapine
Not Available
3-hydroxynevirapine glucuronideDetails
Route of eliminationThus cytochrome P450 metabolism, glucuronide conjugation, and urinary excretion of glucuronidated metabolites represent the primary route of nevirapine biotransformation and elimination in humans. Only a small fraction (<5%) of the radioactivity in urine (representing <3% of the total dose) was made up of parent compound; therefore, renal excretion plays a minor role in elimination of the parent compound.
Half life45 hours
ClearanceNot Available
ToxicitySymptoms of overdose include edema, erythema nodosum, fatigue, fever, headache, insomnia, nausea, pulmonaryinfiltrates, rash, vertigo, vomiting, and weight decrease. The most common adverse reaction is rash.
Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategorySMPDB ID
Nevirapine Action PathwayDrug actionSMP00743
Nevirapine Metabolism PathwayDrug metabolismSMP00642
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9756
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5606
P-glycoprotein inhibitor INon-inhibitor0.6488
P-glycoprotein inhibitor IINon-inhibitor0.8514
Renal organic cation transporterNon-inhibitor0.7124
CYP450 2C9 substrateNon-substrate0.6179
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6413
CYP450 1A2 substrateInhibitor0.6175
CYP450 2C9 inhibitorNon-inhibitor0.8009
CYP450 2D6 inhibitorNon-inhibitor0.9451
CYP450 2C19 inhibitorNon-inhibitor0.7971
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5443
Ames testAMES toxic0.5952
CarcinogenicityNon-carcinogens0.9383
BiodegradationNot ready biodegradable0.964
Rat acute toxicity2.6729 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9827
hERG inhibition (predictor II)Non-inhibitor0.8321
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Suspensionoral50 mg/5mL
Tabletoral200 mg/1
Tablet, coatedoral200 mg/1
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral400 mg/1
Tabletoral400 mg/1
Tabletoral200 mg
Tablet (extended-release)oral400 mg
Prices
Unit descriptionCostUnit
Viramune 200 mg tablet9.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2030056 No1995-10-172010-11-15Canada
US5366972 No1995-05-222012-05-22Us
US8460704 No2009-03-122029-03-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point196.06Not Available
water solubility0.7046 mg/LNot Available
logP2.5Not Available
Caco2 permeability-4.52ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP1.75ALOGPS
logP2.49ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)10.37ChemAxon
pKa (Strongest Basic)5.06ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area58.12 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity77.48 m3·mol-1ChemAxon
Polarizability27.8 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US5366972
General ReferencesNot Available
External Links
ATC CodesJ05AG01J05AR05J05AR07
AHFS Codes
  • 08:18.08.16
PDB EntriesNot Available
FDA labelDownload (423 KB)
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Nevirapine.
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Nevirapine.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Nevirapine resulting in a loss in efficacy.
AtazanavirThe serum concentration of Nevirapine can be increased when it is combined with Atazanavir.
BexaroteneThe serum concentration of Nevirapine can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Nevirapine can be decreased when it is combined with Bosentan.
BupropionThe metabolism of Bupropion can be increased when combined with Nevirapine.
CarbamazepineThe serum concentration of Nevirapine can be decreased when it is combined with Carbamazepine.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Nevirapine.
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Nevirapine.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Nevirapine.
DabrafenibThe serum concentration of Nevirapine can be decreased when it is combined with Dabrafenib.
DarunavirThe serum concentration of Nevirapine can be increased when it is combined with Darunavir.
DeferasiroxThe serum concentration of Nevirapine can be decreased when it is combined with Deferasirox.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Nevirapine.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Nevirapine.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Nevirapine.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Nevirapine.
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Nevirapine.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Nevirapine.
FluconazoleThe serum concentration of Nevirapine can be increased when it is combined with Fluconazole.
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Nevirapine resulting in a loss in efficacy.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Nevirapine.
IfosfamideThe metabolism of Ifosfamide can be increased when combined with Nevirapine.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Nevirapine.
IrinotecanThe metabolism of Irinotecan can be increased when combined with Nevirapine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Nevirapine.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Nevirapine.
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Nevirapine.
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Nevirapine.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone Acetate can be decreased when it is combined with Nevirapine.
MethadoneThe metabolism of Methadone can be increased when combined with Nevirapine.
MitotaneThe serum concentration of Nevirapine can be decreased when it is combined with Mitotane.
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Nevirapine resulting in a loss in efficacy.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Nevirapine.
NorethisteroneThe serum concentration of Norethindrone can be decreased when it is combined with Nevirapine.
PhenytoinThe metabolism of Nevirapine can be increased when combined with Phenytoin.
PromethazineThe metabolism of Promethazine can be increased when combined with Nevirapine.
RifabutinThe serum concentration of Nevirapine can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Nevirapine can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Nevirapine.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Nevirapine.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nevirapine.
SelegilineThe metabolism of Selegiline can be increased when combined with Nevirapine.
SiltuximabThe serum concentration of Nevirapine can be decreased when it is combined with Siltuximab.
St. John's WortThe serum concentration of Nevirapine can be decreased when it is combined with St. John&#39;s Wort.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Nevirapine.
TocilizumabThe serum concentration of Nevirapine can be decreased when it is combined with Tocilizumab.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Nevirapine.
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna-dna hybrid ribonuclease activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72547
Molecular Weight:
65223.615 Da
References
  1. Ambrose Z, Herman BD, Sheen CW, Zelina S, Moore KL, Tachedjian G, Nissley DV, Sluis-Cremer N: The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J Virol. 2009 Apr;83(8):3826-33. doi: 10.1128/JVI.01968-08. Epub 2009 Feb 4. [PubMed:19193782 ]
  2. Nikolenko GN, Delviks-Frankenberry KA, Pathak VK: A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol. 2010 May;84(10):5238-49. doi: 10.1128/JVI.01545-09. Epub 2010 Mar 10. [PubMed:20219933 ]
  3. Ghosn J, Chaix ML, Delaugerre C: HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev. 2009 Jul-Sep;11(3):165-73. [PubMed:19654858 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on June 29, 2016 01:52